Hoeks M P A, Middelburg R A, Romeijn B, Blijlevens N M A, van Kraaij M G J, Zwaginga J J
Center for Clinical Transfusion Research, Sanquin Research, Leiden, The Netherlands.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Vox Sang. 2018 Feb;113(2):152-159. doi: 10.1111/vox.12617. Epub 2017 Dec 19.
Evidence-based guidelines on optimal triggers for red blood cell (RBC) transfusion in patients with haematological malignancies exist, but the evidence is weak. Secondary iron overload is an often overlooked chronic complication of RBC transfusions, and also here, guidelines are either lacking or lack international consensus. Our aim was to evaluate the triggers for RBC transfusion support and management of secondary iron overload among haematologists in the Netherlands.
For this cross-sectional study, all haematologists and haematologists in training in the Netherlands were sent a web-based, 25-question survey including three clinical scenarios. The survey distribution took place between 19 November 2015 and 26 January 2016.
Seventy-seven responses were received (24%), well distributed among community and university hospitals. A wide variation in haemoglobin triggers existed: 5·6-9·5 g/dl (median: 8·0 g/dl). Personalization of this trigger was mostly based on (estimated) cardiopulmonary compensation capacity of patients. About 65% of respondents reported two RBC units per transfusion episode (range 1-3). For monitoring secondary iron overload, serum ferritin was most frequently measured (97%), while a value of 1000-1500 μg/l was the most common cut-off to initiate treatment (39%). For 81% of respondents, phlebotomies were the first choice of treatment, although often the haemoglobin level was considered a limiting factor.
Our results confirm large reported variation in daily practice among haematologists in the Netherlands regarding RBC transfusion support and management of secondary iron overload. Future studies providing better evidence are needed to improve guidelines specific for patients with haematological malignancies.
关于血液系统恶性肿瘤患者红细胞(RBC)输血最佳触发因素已有循证指南,但证据不足。继发性铁过载是红细胞输血常被忽视的慢性并发症,在此方面,要么缺乏指南,要么缺乏国际共识。我们的目的是评估荷兰血液科医生对红细胞输血支持的触发因素及继发性铁过载的管理情况。
在这项横断面研究中,向荷兰所有血液科医生及实习血液科医生发送了一份基于网络的、包含25个问题及三个临床病例的调查问卷。调查于2015年11月19日至2016年1月26日进行。
共收到77份回复(24%),在社区医院和大学医院分布良好。血红蛋白触发值存在很大差异:5.6 - 9.5 g/dl(中位数:8.0 g/dl)。该触发值的个体化主要基于患者(估计的)心肺代偿能力。约65%的受访者报告每次输血输注两个红细胞单位(范围1 - 3个)。对于监测继发性铁过载,最常检测血清铁蛋白(97%),而启动治疗的最常见临界值为1000 - 1500 μg/l(39%)。对于81%的受访者,静脉放血是首选治疗方法,尽管血红蛋白水平常被视为限制因素。
我们的结果证实,荷兰血液科医生在红细胞输血支持及继发性铁过载管理的日常实践中存在很大差异。需要开展提供更好证据的未来研究,以完善针对血液系统恶性肿瘤患者的指南。